Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H1 2016', provides in depth analysis on Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted pipeline therapeutics. The report provides comprehensive information on the Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - The report reviews Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects - The report assesses Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) Overview 7 Therapeutics Development 8 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Stage of Development 8 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Therapy Area 9 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Indication 10 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Products under Development by Companies 13 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development 19 Actelion Ltd 19 Eisai Co., Ltd. 20 Evotec AG 21 Heptares Therapeutics Limited 22 Johnson & Johnson 23 Merck & Co., Inc. 24 Novartis AG 25 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles 26 DORA-12 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 HTL-6641 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 JNJ-42847922 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 lemborexant - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 MK-8133 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Small Molecule to Inhibit OX2R for Insomnia - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecules to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Dormant Projects 38 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products 39 Orexin Receptor Type 2 (Ox2R or Hypocretin Receptor Type 2 or HCRTR2) - Featured News & Press Releases 40 Mar 11, 2016: Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202 40 Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients 41 Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder 41 Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202 42 Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist 42 Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist 43 Feb 03, 2015: Merck's Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 44 Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia 45 Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 46 Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan 46 Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial 47 Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia 47 Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck's Investigational Medicine for Insomnia 49 May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose 50 May 20, 2013: Merck's Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says 50 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 18 Pipeline by Actelion Ltd, H1 2016 19 Pipeline by Eisai Co., Ltd., H1 2016 20 Pipeline by Evotec AG, H1 2016 21 Pipeline by Heptares Therapeutics Limited, H1 2016 22 Pipeline by Johnson & Johnson, H1 2016 23 Pipeline by Merck & Co., Inc., H1 2016 24 Pipeline by Novartis AG, H1 2016 25 Dormant Projects, H1 2016 38 Discontinued Products, H1 2016 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
